Clinical Trials Logo

Filter by:
NCT ID: NCT05072652 Completed - Muscle Weakness Clinical Trials

Short Term Immobilization of the Lower Limb

STILL
Start date: October 11, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to determine the effects of one week of knee-joint immobilization on muscle size, strength, neuromuscular function, and brain function. In addition, the effects of two different interventions (i.e., neuromuscular electrical stimulation and action observation/mental imagery) throughout immobilization will be determined. Following the immobilization period, participants that have lost strength will be rehabilitated with twice weekly resistance training sessions, and sex-based differences in rehabilitation timelines will be examined.

NCT ID: NCT05072639 Completed - Urologic Cancer Clinical Trials

Preoperative Guided Imagery in Patients Undergoing Urologic Surgery

Start date: March 25, 2017
Phase: N/A
Study type: Interventional

This is a prospective randomized controlled trial of patients undergoing major urologic-oncologic surgery at the University of California, San Francisco (UCSF) Medical Center and the Helen Diller Family Comprehensive Cancer Center. This clinical trial examines the effect of guided meditation before surgery on the levels of anxiety, stress, sleep disturbance, and quality of life among patients scheduled to undergo a major urologic surgery for cancer. A cancer diagnosis and the treatments associated with it can be very stressful for patients, leading to depression, sleep disturbances, and lower quality of life. Mind-body practices such as guided meditation have been used for thousands of years to reduce the effects of chronic stress and to improve quality of life. This clinical trial examines the effects of guided meditation on the stress, depression, and quality of life levels of patients undergoing urologic surgery for their cancer.

NCT ID: NCT05072470 Completed - Hearing Loss Clinical Trials

Benefits of Assistive Listening Device for Speech Intelligibility

Start date: October 18, 2021
Phase: N/A
Study type: Interventional

Speech intelligibility in noise will be evaluated in adults with moderate to moderate-severe sensorineural hearing loss, using an assistive listening device and hearing aid, and compared to speech intelligibility in noise using hearing aids alone.

NCT ID: NCT05072457 Completed - Clinical trials for Hearing Loss, Sensorineural

Benefit of Assistive Listening Device for Lateralization

Start date: October 18, 2021
Phase: N/A
Study type: Interventional

Speech intelligibility in noise will be evaluated in adults with moderate to moderate-severe sensorineural hearing loss using a Phonak Roger microphone and hearing aid with compatible Phonak Roger receiver. Target speech will be presented from multiple directions while competing diffuse background noise is presented simultaneously. Participants will repeat back words and percent correct is calculated.

NCT ID: NCT05072444 Completed - Clinical trials for Bacterial Infections

Drug-Drug Interaction Study of IV QPX2014 Combined With QPX7728 in Healthy Adult Subjects

Start date: November 15, 2021
Phase: Phase 1
Study type: Interventional

QPX7728 is an ultra-broad-spectrum beta-lactamase inhibitor, with activity against numerous beta-lactamases, including class A extended spectrum betalactamases (ESBLs), class C cephalosporinases, and extended spectrum class D oxacillinases (OXA) that can hydrolyze cephalosporins and can be found in Enterobacteriaceae and Pseudomonas aeruginosa (P. aeruginosa). QPX7728 is also a potent inhibitor of carbapenemases from all molecular classes, such as class A Klebsiella pheumoniae carbapenemase (KPC), class B New-Dehli Metalo-beta-lactamase (NDM) and Verona integron-encoded metallo-betalactamase (VIM), and class D OXA-48 that are found in carbapenem resistant Enterobacteriaceae, and also class D carbapenemases such as OXA-23 that are found in carbapenem resistant Acinetobacter baumannii.

NCT ID: NCT05072301 Completed - Smoking Cessation Clinical Trials

Preliminary Test of Reactive Carrot Incentives in a Practice Quit Environment With Contingency Management Incentives

Start date: October 13, 2021
Phase: N/A
Study type: Interventional

The primary aim of this study is to pilot test a novel reactive carrot approach for improving individuals' ability to stick to a "practice quit" program in a smoking cessation context. In this study, the treatment gives subjects an offer to forego a monetary incentive to forego the opportunity to receive subsequent abstention (contingency management) rewards.

NCT ID: NCT05072145 Completed - Sepsis Clinical Trials

Evaluating Tele-Emergency Care in Costs and Outcomes for Rural Sepsis Patients

TELE-Cost
Start date: April 1, 2022
Phase:
Study type: Observational

Sepsis is a life-threatening emergency for which provider-to-provider telemedicine has been used to improve quality of care. The objective of this study is to measure the impact of rural tele-emergency consultation on long-term health care costs and outcomes through decreasing organ failure, hospital length-of-stay, and readmissions.

NCT ID: NCT05072080 Completed - Chikungunya Virus Clinical Trials

A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317

Start date: September 29, 2021
Phase: Phase 3
Study type: Interventional

The goal of this multi-center, randomized, double blind, placebo controlled study is to evaluate the safety and immunogenicity of PXVX0317 in healthy adult and adolescent subjects.

NCT ID: NCT05071807 Completed - Clinical trials for Cardiovascular Diseases

Cardiometabolic Effects of Pecans as a Snack

Start date: August 15, 2022
Phase: Phase 2
Study type: Interventional

A randomized, 2-arm, parallel trial will be conducted to examine the effect of pecans on markers of peripheral vascular health, lipids and lipoproteins, blood pressure, and glycemic control.

NCT ID: NCT05071729 Completed - Clinical trials for Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men

A Study to Learn How Elinzanetant Moves Into, Through, and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Kidneys That do Not Work as Well as They Should Compared to Participants Whose Kidneys Work Normally

Start date: October 14, 2021
Phase: Phase 1
Study type: Interventional

Researchers are looking for a better way to treat people who have vasomotor symptoms (VMS). The symptoms of VMS are hot flashes. These symptoms can be caused by changes in sex hormone levels. An example of a change in sex hormone levels is when a woman reaches the time in their life where they no longer have their period. Hormones are substances in the blood that help body organs to work in specific ways. Women who no longer have their period may have a protein called neurokinin sending more signals than usual to other parts of the body. Researchers think that this may play a role in causing VMS. In this study, the researchers want to learn more about a new substance called elinzanetant. Researchers think elinzanetant may help people with VMS. It works by blocking neurokinin from sending signals to other parts of the body. There are treatments available for VMS, but these do not work for all people and may cause medical problems for some people. The main purpose of this study is to help the researchers learn more about how elinzanetant moves into, through and out of the body in participants with kidneys that do not work as well as they should compared to healthy participants whose kidneys work normally. To do this, the doctors will take blood samples from the participants at different times during the study and measure the levels of elinzanetant in the blood. This will help the researchers learn more about whether elinzanetant could be given to treat VMS in people who also have kidneys that do not work as well as they should. This study will include adult participants who have kidneys that do not work as well as they should and participants whose kidneys work normally. The participants who have kidneys that do not work as well as they should will be split into 2 groups based on how severe their kidney problems are. All of the participants will take elinzanetant once as a tablet by mouth. The participants will be in the study for about 1 month and will stay at their study site for 7 days in a row. During this visit, the participants will: - have their overall health checked - have scans of their heart taken using an electrocardiogram - have blood and urine samples taken - answer questions about how they are feeling, what medications they are taking, and what adverse events they are having The doctors will keep track of any adverse events. An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments.